NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Forecast, Price & News $15.80 -0.38 (-2.35%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$15.56▼$16.4150-Day Range$13.61▼$17.3752-Week Range$9.32▼$24.38Volume30,692 shsAverage Volume68,952 shsMarket Capitalization$524.56 millionP/E RatioN/ADividend YieldN/APrice Target$21.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Entrada Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside37.3% Upside$21.50 Price TargetShort InterestBearish8.63% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.73Based on 2 Articles This WeekInsider TradingSelling Shares$505,297 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.07) to ($2.35) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.62 out of 5 starsMedical Sector879th out of 972 stocksPharmaceutical Preparations Industry412th out of 451 stocks 3.3 Analyst's Opinion Consensus RatingEntrada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.50, Entrada Therapeutics has a forecasted upside of 37.3% from its current price of $15.66.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.63% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 26.1, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRDA. Previous Next 2.1 News and Social Media Coverage News SentimentEntrada Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Entrada Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Entrada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $505,297.00 in company stock.Percentage Held by InsidersOnly 7.58% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions77.59% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Entrada Therapeutics are expected to decrease in the coming year, from ($2.07) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 2.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Entrada Therapeutics (NASDAQ:TRDA) StockEntrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More TRDA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRDA Stock News HeadlinesSeptember 24, 2023 | americanbankingnews.comEntrada Therapeutics (NASDAQ:TRDA) Rating Reiterated by HC WainwrightSeptember 21, 2023 | finance.yahoo.comEntrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophySeptember 29, 2023 | Weiss Ratings (Ad)Overlooked AI Stock Gets Urgent "Buy"We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.September 17, 2023 | barrons.comEntrada Therapeutics Inc.September 16, 2023 | finance.yahoo.comInsider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 SharesSeptember 12, 2023 | bizjournals.comGood News Tuesday: Entrada Therapeutics supports initiatives to help those with Duchenne Muscular DystrophySeptember 7, 2023 | finance.yahoo.comEntrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy CommunityAugust 29, 2023 | finance.yahoo.comEntrada Therapeutics to Present at Upcoming Investor ConferencesSeptember 29, 2023 | Altimetry (Ad)Seven millionaires secretly enable market shock?A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.August 10, 2023 | finance.yahoo.comEntrada Therapeutics Appoints Gina Chapman to its Board of DirectorsAugust 9, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)August 8, 2023 | finance.yahoo.comEntrada Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 8, 2023 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue EstimatesAugust 4, 2023 | finance.yahoo.comEntrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 yearAugust 3, 2023 | seekingalpha.comEntrada Therapeutics: Early Stage But InterestingAugust 2, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Entrada Therapeutics Inc (TRDA) and Minerva Neurosciences (NERV)August 1, 2023 | finance.yahoo.comEntrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular DystrophyJune 6, 2023 | finance.yahoo.comEntrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare ConferenceMay 24, 2023 | msn.comHC Wainwright & Co. Reiterates Entrada Therapeutics (TRDA) Buy RecommendationMay 24, 2023 | markets.businessinsider.comEntrada Therapeutics Inc (TRDA) Receives a Buy from H.C. WainwrightMay 15, 2023 | finance.yahoo.comSome Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EstimatesMay 13, 2023 | finance.yahoo.comEntrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMay 12, 2023 | seekingalpha.comEntrada Therapeutics Stock Deserves Higher Resonance After Q1 2023 ReportMay 11, 2023 | marketwatch.com8-K: Entrada Therapeutics, Inc.May 11, 2023 | markets.businessinsider.comGoldman Sachs Sticks to Its Hold Rating for Entrada Therapeutics Inc (TRDA)May 10, 2023 | finanznachrichten.deEntrada Therapeutics, Inc.: Entrada Therapeutics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comEntrada Therapeutics Reports First Quarter 2023 Financial ResultsSee More Headlines Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Company Calendar Last Earnings8/08/2023Today9/29/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRDA CUSIPN/A CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees131Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.50 High Stock Price Forecast$25.00 Low Stock Price Forecast$18.00 Forecasted Upside/Downside+32.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,620,000.00 Net MarginsN/A Pretax Margin-149.60% Return on Equity-37.34% Return on Assets-22.02% Debt Debt-to-Equity RatioN/A Current Ratio3.10 Quick Ratio3.10 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.77 per share Price / Book2.39Miscellaneous Outstanding Shares33,200,000Free Float30,681,000Market Cap$537.18 million OptionableNot Optionable Beta-0.32 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Dipal Doshi (Age 47)Pres, CEO & Director Comp: $902.08kMr. Nathan J. Dowden (Age 52)Chief Operating Officer Comp: $654.6kDr. Natarajan Sethuraman Ph.D. (Age 61)Chief Scientific Officer Comp: $654.6kMr. Kory James Wentworth CPA (Age 43)CFO & Treasurer Dr. Jared Cohen J.D.Ph.D., Gen. CounselMs. Kerry Robert M.S.Sr. VP of PeopleDr. Nerissa C. Kreher M.B.A. (Age 50)M.D., M.S., Chief Medical Officer Ms. Karla MacDonaldChief Corp. Affairs OfficerMore ExecutivesKey CompetitorsHarrow HealthNASDAQ:HROWBiomea FusionNASDAQ:BMEASavaraNASDAQ:SVRAEvolusNASDAQ:EOLSAnaptysBioNASDAQ:ANABView All CompetitorsInsiders & InstitutionsBarclays PLCSold 3,788 shares on 9/21/2023Ownership: 0.019%Dipal DoshiSold 1,000 sharesTotal: $15,000.00 ($15.00/share)Kory James WentworthSold 950 sharesTotal: $12,806.00 ($13.48/share)Nathan J DowdenSold 972 sharesTotal: $13,092.84 ($13.47/share)Nerissa KreherSold 892 sharesTotal: $12,024.16 ($13.48/share)View All Insider TransactionsView All Institutional Transactions TRDA Stock - Frequently Asked Questions Should I buy or sell Entrada Therapeutics stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entrada Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TRDA shares. View TRDA analyst ratings or view top-rated stocks. What is Entrada Therapeutics' stock price forecast for 2023? 3 brokerages have issued 12 month price objectives for Entrada Therapeutics' stock. Their TRDA share price forecasts range from $18.00 to $25.00. On average, they expect the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 32.9% from the stock's current price. View analysts price targets for TRDA or view top-rated stocks among Wall Street analysts. How have TRDA shares performed in 2023? Entrada Therapeutics' stock was trading at $13.52 at the beginning of 2023. Since then, TRDA stock has increased by 19.7% and is now trading at $16.18. View the best growth stocks for 2023 here. When is Entrada Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our TRDA earnings forecast. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.35. The company had revenue of $18.17 million for the quarter, compared to the consensus estimate of $19.56 million. When did Entrada Therapeutics IPO? (TRDA) raised $182 million in an IPO on Friday, October 29th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share. What is Entrada Therapeutics' stock symbol? Entrada Therapeutics trades on the NASDAQ under the ticker symbol "TRDA." How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Entrada Therapeutics' stock price today? One share of TRDA stock can currently be purchased for approximately $16.18. How much money does Entrada Therapeutics make? Entrada Therapeutics (NASDAQ:TRDA) has a market capitalization of $537.18 million. The company earns $-94,620,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis. How many employees does Entrada Therapeutics have? The company employs 131 workers across the globe. How can I contact Entrada Therapeutics? The official website for the company is www.entradatx.com. The company can be reached via phone at 857-520-9158 or via email at investors@entradatx.com. This page (NASDAQ:TRDA) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.